ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 0304 • ACR Convergence 2024

    Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio

    doryan Garcia Olivas1, Judith Hernández Sánchez1, luis Bausá Gimeno1, Javier Nóvoa Medina1, Sergio Machín1, Maria Ángeles Acosta-Mérida1, Diana Botello-Corzo1, daniel Batista Perdomo1, José Ángel Hernández Beriain2 and Beatriz Tejera Segura1, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, 2Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
  • Abstract Number: 0842 • ACR Convergence 2024

    The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)

    Reyhan Kose Cobanoglu1, Rohan Willis2, Diana Paredes-Ruiz3, Maria G Tektonidou4, Vittorio Pengo5, Savino Sciascia6, Cecilia Nalli7, Flavio Victor Signorelli8, Paul Fortin9, Maria Efthymiou10, H Michael Belmont11, Michelle Petri12, Ricard Cervera13, Megan Barber14, TATSUYA ATSUMI15, Chary Lopez-Pedrera16, Jason Knight17, David Branch18, Nina Kello19, Lanlan Ji20, Esther Rodriguez-Almaraz21, Bahar Artim Esen22, Jose Pardos Gea23, Rosana Quintana24, Giulia Pazzola25, Hui Shi26, Ali Duarte-Garcia27, Pierluigi Meroni28, Robert Roubey29, Maria Laura Bertolaccini30, Hannah Cohen31, Danieli Andrade32 and Doruk Erkan33, and on behalf of APS ACTION, 1Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 2University of Texas Medical Branch, Galveston, TX, 3Biocruces Bizkaia Health Research Institute, Bizkaia, Spain, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Torino, Turin, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 9Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 10University College London, London, United Kingdom, 11NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 15Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 16IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 17University of Michigan, Ann Arbor, MI, 18University of Utah and Intermountain Healthcare, Salt Lake City, UT, 19Northwell Health, Brooklyn, NY, 20Peking University First Hospital, Peking, China (People's Republic), 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 23Vall d'Hebron University Hospital, Barcelona, Spain, 24Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 25Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 26Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 27Mayo Clinic, Rochester, MN, 28IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 29Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 30King's College London, London, United Kingdom, 31University College London Hospitals NHS Foundation Trust, London, United Kingdom, 32University of São Paulo, São Paulo, SP, Brazil, 33Hospital for Special Surgery, New York, NY

    Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases…
  • Abstract Number: 1345 • ACR Convergence 2024

    Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study

    Cristina Corrales Selaya1, Nuria Vegas Revenga2, Carmen Secada Gómez3, Jose Antonio parra-Blanco4, Virginia Portilla-González4, Ricardo Blanco-Alonso5, Miguel Angel Gonzalez-Gay6, ivan Ferraz-Amaro7 and alfonso Corrales-Martínez8, 1Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, 2Hospital Galdakao- Usansolo, Galdakao, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 6University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 7Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 8Hospital Universitario Marques de Valdecilla, Santander, Spain

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
  • Abstract Number: 2138 • ACR Convergence 2024

    DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

    Edgar Wiebe1, Elisa Schilling2, Dörte Huscher2, Zhivana Boydzhieva3, andriko Palmowski4, Sandra Hermann5, burkhard Muche5, Gerhard Krönke5 and FRANK HARTMUT DR. BUTTGEREIT1, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Charité Universittsmedizin, Berlin, Germany, 4Charité - Universittsmedizin Berlin, Berlin, Germany, 5Rheumatology, Charité, Berlin, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone.…
  • Abstract Number: 2652 • ACR Convergence 2024

    Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study

    Geoffroy Peyrac1, Natalie Lomba Goncalves1, Aïcha Kante2, Patrice Cacoub3, Karim Sacré4, David Saadoun5, Thomas Papo4, Jean-François Alexandra6, Valentin Pagis7, Venceslas Bourdin1, Pascal Richette8, Arnaud Vanjak9, Augustin Latourte10, Dikélélé Elessa7, William Bigot1, Ruxandra burlacu7, Karine Champion1, Blanca Amador Borrero7, Amanda Lopes1, Audrey Depond7, Peggy Reiner11, Homa Adle-Biassette12, Aude Couturier13, Philippe Bonnin14, Alexandre Boutigny15, Frédéric Paycha16, Anne Couvelard17, Alexis Régent18, Benjamin Chaigne19, Yann Nguyen20, Agnès lefort20, Olivier Bory21, Elisabeth Aslangul22, stephane mouly1, Damien Sène1, Viet-Thi Tran23 and Cloé Comarmond1, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 2Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 3Sorbonne Université, Paris, 4Université Paris Cité, Paris, France, 5Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, 6INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, 7Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, 8Lariboisière Hospital, Paris, France, 9Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, 10AP-HP, Paris, France, 11Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, 12Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, 13Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, 14Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 15Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, 16Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, 17Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, 18National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 19Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, 20Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, 21Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, 22Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, 23Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France

    Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
  • Abstract Number: 0337 • ACR Convergence 2024

    Characterization of Statin Induced Myopathy in the Hospital Setting

    Olivia Yang1, KUMAR VENKAT2, Jeffery Durbin3 and Scott Kubomoto1, 1Riverside Community Hospital, Riverside, CA, 2Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, 3HCA Healthcare Physicians Services Group, Brentwood, TN

    Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
  • Abstract Number: 0843 • ACR Convergence 2024

    External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors

    Jacob J.E. Koopman1, Jing Cui1, Hongshu Guan1, Emma Stevens1, Emily Oakes1 and Karen Costenbader2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental…
  • Abstract Number: 1390 • ACR Convergence 2024

    One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)

    Luis Gomez-Lechon Quiros1, José Miguel Sequí-Sabater2, Amalia Rueda3, Costas Torrijo Nerea4, Carlos Valera-Ribera5, Juan Miguel López-Gómez6 and Antonio Alvarez-Cienfuegos7, 1Hospital Francesc de Borja, Valéncia, Spain, 2La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, 3Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 4Generalitat valenciana, Valencia, Spain, 5Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, 6Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, 7Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
  • Abstract Number: 2203 • ACR Convergence 2024

    The Association of Autoantibodies with Clinical Manifestations and Long-term Outcomes in Juvenile- and Adult-onset Systemic Sclerosis

    Hideaki Tsuji1, Ryosuke Hiwa1, Mirei Shirakashi2, Shuji Akizuki3, Ran Nakashima1, Akira Onishi4, Hajime Yoshifuji1, Masao Tanaka4 and Akio Morinobu5, 1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, 4Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, 5Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan

    Background/Purpose: Our aim is to explore whether clinical features and long-term outcomes depend on autoantibodies in juvenile- and adult-onset systemic sclerosis (SSc), since they were…
  • Abstract Number: 2693 • ACR Convergence 2024

    Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab

    Ellen Romich1, Joshua Baker2, Ian Green2, Rennie Rhee2, Carol McAlear2, Ulrich Specks3, Rona Smith4, David Jayne4 and Peter Merkel2, and the RITAZAREM Investigators, 1University of Pennsylvania, Media, PA, 2University of Pennsylvania, Philadelphia, PA, 3Mayo Clinic, Rochester, MN, 4University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
  • Abstract Number: 0477 • ACR Convergence 2024

    The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Hari Prasanna1, Charles Inderjeeth2, Johannes Nossent3 and KHALID ALMUTAIRI4, 1University of Western Australia, Perth, Western Australia, Australia, 2SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, 3University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 4The University of Western Australia, Perth, Western Australia, Australia

    Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
  • Abstract Number: 0866 • ACR Convergence 2024

    Cross-sectional Analysis of Erosive Hand Osteoarthritis and Fracture Risk

    Avanika Mahajan1, carolyn mead harvey2, Chris Grilli3 and Megan Sullivan3, 1Mayo Clinic - - Scottsdale, AZ, Phoenix, AZ, 2Mayo Clinic Florida, Jacksonville, FL, 3Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Erosive hand osteoarthritis (EHOA) is a subtype of hand OA that primarily impacts the interphalangeal joints resulting in subchondral bone erosion and cortical destruction.…
  • Abstract Number: 1487 • ACR Convergence 2024

    Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia

    Fan Lian and Qingying Fang, First Affiliated Hospital of Sun Yat-sen University, guangzhou, China (People's Republic)

    Background/Purpose: To compare the pregnancy outcomes of patients with systemic lupus erythematosus (SLE) complicated with thrombocytopenia and those without, and to analyze the related risk…
  • Abstract Number: 2287 • ACR Convergence 2024

    Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study

    Christine Xue1, Monica Guma2 and Katherine Nguyen2, 1UC San Diego, San Diego, CA, 2UC San Diego, San Diego

    Background/Purpose:  Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
  • Abstract Number: 0483 • ACR Convergence 2024

    Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

    Misti Paudel1, Shravani Chitineni1, Ruogu Li2, Chinmayi Naik3, Nancy Shadick3, Michael Weinblatt4 and Daniel Solomon5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Prior studies have evaluated the risk factors for difficult-to-treat RA (D2T-RA) but have not applied EULAR’s full criteria for D2T-RA in a longitudinal data…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology